결핵 검사 시장 : 검사 유형, 기술, 검체 유형, 최종 사용자, 유통 채널, 용도별 - 세계 시장 예측(2026-2032년)

The Tuberculosis Testing Market is projected to grow by USD 3.68 billion at a CAGR of 6.60% by 2032.

Tuberculosis testing is central to global TB control because timely diagnosis determines whether patients receive curative therapy, drug-resistance evaluation, and public health follow-up. According to the World Health Organization, an estimated 10.8 million people developed TB in 2023, and 1.25 million people died from the disease, underscoring the need for faster, more accessible diagnostic pathways.

The tuberculosis testing landscape spans tuberculin skin tests, interferon-gamma release assays, smear microscopy, culture, nucleic acid amplification tests, line probe assays, and urine lipoarabinomannan testing for eligible high-risk patients. Demand is being shaped by WHO recommendations favoring rapid molecular diagnostics as initial tests for symptomatic patients, rising drug-resistant TB surveillance needs, and expanded screening among vulnerable populations, including people living with HIV, household contacts, migrants, incarcerated populations, and individuals with diabetes or immunosuppression.

Transformative Shifts in the Tuberculosis Testing Landscape

The tuberculosis testing landscape is shifting from microscopy-led workflows toward rapid molecular testing, decentralized sample collection, and integrated drug-resistance detection. Culture remains essential for comprehensive susceptibility testing, but nucleic acid amplification tests can identify Mycobacterium tuberculosis and rifampicin resistance within hours, helping clinicians initiate appropriate treatment sooner and supporting public health teams in interrupting transmission.

Another major shift is the expansion of active case-finding beyond traditional clinics. Mobile chest X-ray, community sputum collection, digital reporting, contact investigation, and linkage-to-care platforms are improving detection in high-burden settings. These changes support national TB programs seeking to close the gap between estimated TB incidence and the number of people who are bacteriologically confirmed and notified, while also improving access for populations that face geographic, social, or economic barriers to facility-based diagnosis.

Cumulative Impact of Artificial Intelligence on TB Testing

Artificial intelligence is increasingly influencing tuberculosis testing through computer-aided detection for chest radiography, automated laboratory quality checks, workflow prioritization, and predictive outreach. WHO has stated that computer-aided detection software may be used as an alternative to human readers for TB screening and triage in people aged 15 years and older, when implemented with appropriate calibration and confirmatory testing.

AI does not replace microbiological confirmation, but it can accelerate screening, reduce reader variability, and support targeted testing in high-volume environments. The strongest use cases combine AI triage with WHO-recommended rapid molecular tests, laboratory information systems, and governance frameworks covering bias monitoring, data security, local validation, and clinical accountability. As digital chest radiography expands in community and mobile settings, AI-enabled triage is expected to remain most valuable where it shortens the pathway from symptom screening to confirmatory molecular diagnosis and treatment initiation.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific remains the largest burden environment for tuberculosis testing, led by high-incidence countries such as India, China, Indonesia, and the Philippines. The region is prioritizing rapid molecular diagnostics, private-sector notification, community screening, and drug-resistance detection to improve case finding and shorten time to treatment. Large population bases, diverse healthcare access levels, and national TB elimination strategies make Asia-Pacific a core region for molecular tuberculosis diagnostics, digital chest X-ray screening, and laboratory network strengthening.

North America and Europe are lower-incidence regions, but testing demand persists across migrants, people experiencing homelessness, correctional settings, healthcare workers, close contacts, and immunocompromised patients. In these regions, TB testing is closely linked to latent tuberculosis infection management, infection control, high-quality laboratory confirmation, and surveillance. Latin America faces urban transmission, access gaps, and uneven diagnostic capacity, creating a need for faster testing in underserved communities and stronger linkage-to-care systems. The Middle East has heterogeneous needs linked to migrant labor, border health, and national screening programs, while Africa carries a high TB and TB/HIV burden, making rapid molecular tests, urine LAM testing for eligible people with HIV, decentralized specimen referral, and integrated TB-HIV diagnostic services especially important.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are expanding molecular tuberculosis testing, digital chest X-ray screening, and community-based case finding to address persistent transmission across high-burden and lower-burden member states. The GCC emphasizes workforce screening, migrant health protocols, centralized laboratory quality, and infection prevention in highly mobile populations. The European Union supports standardized surveillance, cross-border reporting, antimicrobial resistance monitoring, and latent TB infection management among risk groups, with testing strategies shaped by low-incidence elimination goals and migration-related health priorities.

BRICS countries represent a major share of the global TB burden and include several settings with substantial drug-resistant TB challenges, making the group critical to diagnostic adoption, local production, procurement scale, and national program implementation. G7 countries influence tuberculosis testing through innovation funding, regulatory expectations, global health financing, laboratory standards, and support for high-burden countries. NATO members focus on resilient healthcare systems, military readiness, outbreak preparedness, and infectious disease surveillance that includes TB risk management for deployed personnel, mobile populations, and vulnerable communities.

Key Country Insights Across Major Tuberculosis Testing Markets

The United States and Canada maintain low TB incidence but rely on targeted testing, contact investigations, and latent TB screening among higher-risk populations, including people born in countries with higher TB burden, individuals with HIV, and immunocompromised patients. Mexico and Brazil face larger public health needs, with molecular diagnostics supporting earlier detection in urban, remote, and underserved communities. The United Kingdom, Germany, France, Italy, and Spain emphasize migrant screening, laboratory quality, contact tracing, and latent TB prevention, while Russia remains a priority country for multidrug-resistant and rifampicin-resistant TB diagnostics due to its documented drug-resistant TB burden.

China and India are pivotal due to population scale, national TB elimination strategies, and rapid test deployment across public health networks. India continues to expand molecular testing, private-sector engagement, and active case-finding initiatives, while China combines surveillance, laboratory modernization, and targeted screening in high-risk groups. Japan, Australia, and South Korea combine low-incidence surveillance with advanced laboratory networks, rigorous contact investigation, and targeted latent TB testing. Across these countries, the strongest opportunities are linked to rapid molecular testing, culture and drug-susceptibility testing, digital notification, specimen referral systems, AI-assisted radiology screening, and programs that connect diagnosis to treatment initiation without delay.

Actionable Recommendations for Tuberculosis Testing Industry Leaders

Industry leaders should align product portfolios with WHO-recommended diagnostic algorithms, especially rapid molecular tests that detect TB and key drug-resistance markers. Commercial strategies should prioritize affordability, cartridge availability, instrument uptime, biosafety, specimen logistics, and service models that work in centralized laboratories, district hospitals, mobile screening programs, and decentralized care settings.

Organizations should also invest in interoperable digital reporting, external quality assurance, sample transport, maintenance networks, and AI-enabled screening partnerships. The most defensible strategies will combine validated diagnostics with training, supply continuity, local regulatory engagement, and evidence generation that demonstrates improved case detection, faster treatment initiation, stronger drug-resistance surveillance, and reduced loss to follow-up. Partnerships with public health programs should focus on workflow integration, not only test placement, so that screening, confirmation, reporting, and treatment linkage operate as a single patient-centered pathway.

Research Methodology

This executive summary is based on a structured review of authoritative public health and scientific sources, including WHO guidance, national TB program priorities, CDC and ECDC materials, peer-reviewed diagnostic evidence, regulatory trends, and publicly available health policy information. Insights were triangulated across disease burden, testing algorithms, procurement patterns, diagnostic technology adoption, screening guidance, and laboratory implementation signals.

The methodology emphasizes verified, data-backed interpretation rather than unsupported estimates. Regional, group, and country insights were assessed through the lens of TB incidence, drug-resistant TB burden, TB/HIV co-infection, laboratory capacity, reimbursement conditions, screening policies, and the practical role of molecular diagnostics, culture, immunological testing, urine LAM testing, and AI-assisted radiology. The analysis excludes market sizing, market share, and forecasting, focusing instead on evidence-based shifts in tuberculosis testing access, clinical utility, and public health relevance.

Conclusion

Tuberculosis testing is moving toward faster, more connected, and more patient-centered diagnostic models. The combination of rapid molecular testing, targeted screening, drug-resistance detection, AI-supported triage, and digital linkage-to-care is becoming essential for national TB programs and healthcare providers aiming to reduce transmission, improve treatment outcomes, and address persistent diagnostic gaps.

For industry participants, the opportunity is not limited to test placement. Long-term value will come from reliable access, operational support, data integration, quality assurance, and evidence-based partnerships that help close diagnostic gaps in high-burden countries while maintaining surveillance strength in low-incidence markets. Organizations that support complete diagnostic pathways-from screening and confirmatory testing to reporting and treatment initiation-will be best positioned to contribute to global TB elimination priorities.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Tuberculosis Testing Market, by Test Type

• 7.1. Culture Test
  • 7.1.1. Liquid Culture
  • 7.1.2. Solid Culture
• 7.2. Immunological Test
  • 7.2.1. Elisa
  • 7.2.2. Western Blot
• 7.3. Molecular Test
  • 7.3.1. Line Probe Assay
  • 7.3.2. Pcr
• 7.4. Rapid Diagnostic Test
  • 7.4.1. Chromatographic
  • 7.4.2. Lateral Flow

8. Tuberculosis Testing Market, by Technology

• 8.1. Culture Based Technology
• 8.2. Immunodiagnostic
• 8.3. Lipoarabinomannan Assay
• 8.4. Nucleic Acid Amplification Test

9. Tuberculosis Testing Market, by Sample Type

• 9.1. Blood
• 9.2. Sputum
• 9.3. Urine

10. Tuberculosis Testing Market, by End User

• 10.1. Clinics
• 10.2. Hospitals
• 10.3. Reference Laboratory

11. Tuberculosis Testing Market, by Distribution Channel

• 11.1. Diagnostic Laboratory
• 11.2. Hospital Pharmacy
• 11.3. Online Pharmacy

12. Tuberculosis Testing Market, by Application

• 12.1. Active Tuberculosis
• 12.2. Latent Tuberculosis

13. Tuberculosis Testing Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Tuberculosis Testing Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Tuberculosis Testing Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Becton, Dickinson and Company
• 17.3. Bio-Rad Laboratories, Inc.
• 17.4. Biocartis Group NV
• 17.5. bioMerieux SA
• 17.6. Bruker Corporation.
• 17.7. Creative Diagnostics
• 17.8. Danaher Corporation
• 17.9. DiaSorin S.p.A.
• 17.10. F. Hoffmann-La Roche Ltd.
• 17.11. Fujifilm Holdings Corporation
• 17.12. Hologic, Inc.
• 17.13. Kindstar Globalgene Technology, Inc.
• 17.14. Lionex GmbH
• 17.15. Molbio Diagnostics Limited
• 17.16. QIAGEN N.V.
• 17.17. Revvity, Inc.
• 17.18. SD Biosensor, Inc.
• 17.19. Seegene Inc.
• 17.20. Siemens Healthineers AG
• 17.21. Thermo Fisher Scientific Inc.
• 17.22. Zhejiang Di'an Diagnostics Technology Co., Ltd.